Aims Intracoronary ultrasound studies in humans show that chronic remodelling rather than neointimal hyperplasia is the mechanism of restenosis. Stent implantation limits this remodelling process and significantly reduces restenosis. MMP3 (Stromelysin-1), a member of the matrix metalloproteinase family may play a role in this remodelling. We used a functional polymorphism (with alleles designated 5A or 6A) in the promoter of the MMP3 gene to examine the possible role of MMP3 in restenosis.
Introduction
Percutaneous transluminal coronary angioplasty is a widely used procedure for myocardial revascularization in patients with coronary atherosclerosis, but its effectiveness is often limited by restenosis [1] . This problem has been overcome, but only in part, by the use of intra-coronary stents, which reduce the incidence of restenosis [2] . The molecular processes underlying restenosis are not yet completely elucidated, but two main mechanisms have been implicated, namely vascular remodelling and neointimal hyperplasia (see [3] for references). Intracoronary ultrasound studies in humans suggest that chronic remodelling (vessel constriction) is the major mechanism of restenosis after conventional balloon angioplasty, but neointimal hyperplasia appears to be important when a stent is used [4] . Vascular remodelling is one of the key processes in the development of atherosclerotic changes in the arterial wall. Matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (e.g. tissue inhibitor of metalloproteinase-1, TIMP-1) regulate the accumulation of extracellular matrix during tissue injury, and thus the growth of the atherosclerotic plaque [5] . MMP3 (Stromelysin-1) is a key member of the MMP family, and is known to be present in coronary atherosclerotic plaques [6, 7] . MMP3 has a broad substrate specificity [8] , degrading collagen types II, IV and IX, proteoglycans, laminin, fibronectin, gelatins and elastin, and its expression is primarily regulated at the level of transcription [9] . Recently, a common functional variant in the promoter sequence of the MMP3-1 gene has been reported [10] , in which one allele has a run of six adenosines (6A) while the other has only five (5A). In vitro studies [11] and results of clinical trials [10, 12, 13] suggest that, compared with other genotypes, individuals homozygous for the 6A allele would have lower MMP3 levels in their arterial walls because of reduced gene transcription, which would therefore favour deposition of extracellular matrix and increase vessel constriction. To investigate this in clinical practice, we analysed the relationship between the 5A/6A MMP3 polymorphism and restenosis in a series of 485 consecutive patients undergoing coronary angioplasty with or without stenting.
Materials and methods

Study group
In a routine follow-up programme of cardiac catheterization after coronary angioplasty, 485 patients were recruited from Lille during the period 1994-1997, of whom 198 underwent successful implantation of a Palmaz-Schatz stent. These procedures were performed as previously described [14, 15] .
Angiographic analysis
Quantitative computer-assisted angiographic measurements were performed on end-diastolic frames with use of the CAESAR (Computer-Assisted Evaluation of Stenosis and Restenosis) system as previously reported [14, 15] . The acute gain associated with the procedure was defined as the difference between the minimal lumen diameter immediately after stent implantation and before the procedure. The late loss during the follow-up period was defined as the difference between the minimal lumen diameter immediately after stent implantation and at follow-up. The loss index was defined as the late loss to acute gain ratio. We also gave a categorical estimation of restenosis with the classic criterion of >50% diameters stenosis at follow-up [2] .
Genetic analysis
Amplification of 5A/6A MMP3 polymorphism was performed with the following primers: SLPROT5F AM=5 -GATTACAGACATGGGTCACG-3 ; SLPR OT10=5 -GAATTCACATCACTGCCACC-3 ). Polymerase chain reaction conditions and genotyping using the ABIPrism 377 DNA Sequencing apparatus were previously described [12] .
Statistical analysis
Statistical analyses were performed with the SAS 6.12 software (SAS Institute Inc, Cary, NC). Mean and SD of quantitative data were calculated. Quantitative data were compared with a general linear model according to the 5A/6A MMP3 genotypes. Given the dominant effect deduced from the variable distributions, subjects were categorized in two classes according to their genotype (6A6A vs 6A5A+5A5A). Qualitative data were tested with the use of Pearson's chi-square test. A value of P<0·05 was taken as statistically significant.
Results
The characteristics of the patients without (balloon group) and with stents (stent group) are shown in Table  1 . There were no statistically significant differences between the groups with different genotypes for any variables. In both groups, genotype distribution was that expected from Hardy-Weinberg proportions. The frequencies of the 5A allele were not different between the two groups (balloon=0·52, 95%CI 0·44-0·53; stent=0·49, 95% CI 0·48-0·56). Table 2 shows the quantitative angiography measures according to MMP3 genotypes. For both groups, the initial degree of disease and the effectiveness of angioplasty were similar in all three genotypes as seen by the similar minimal lumen diameter and percentage diameter stenosis, before and after the procedure, and similar acute gain. However at 6 month follow-up, in the balloon group, patients carrying the 6A6A genotype had a more pronounced restenostic process compared to those with either of the other genotypes. Compared to those with one or more 5A allele, those homozygous for the 6A allele had 10·7% smaller minimal lumen diameter (1·42 0·69 mm vs 1·59 0·68 mm P=0·07), and 16% greater percentage diameter stenosis (52 21% vs 45 19%, P=0·012). This resulted in a 53% greater late loss (0·58 0·59 mm vs 0·38 0·59 mm, P=0·012) and a 56% greater loss index (0·53 0·61 vs 0·34 0·70, P=0·038). Compared to the 5A5A+5A6A group, a higher proportion of patients with the 6A6A genotype showed >50% stenosis but this difference did not reach statistical significance (43·6% vs 34·6% P=0·17). By contrast, in the stent group there was no statistically significant association between genotypes and any of these variables. These results were not modified when diabetes and history of unstable angina were taken into account nor when stent indication was considered in the stent group (i.e. elective vs suboptimal or bail out).
Discussion
In this quantitative analysis of restenosis after conventional balloon coronary angioplasty, the data show that patients carrying the 6A6A MMP3 genotype had greater late luminal loss compared to patients with other genotypes. The mechanism of this association has been suggested by in vitro studies of promoter strength that showed a lower activity of the 6A promoter compared to that of the 5A allele in both cultured fibroblasts and vascular smooth muscle cells [11] . Thus, subjects with the 6A6A genotype would be predicted to have lower activity of MMP3 in the vessel wall and in atherosclerotic lesions than those with other genotypes, and this lower proteolytic activity would result in less remodelling and thus faster deposition of extracellular matrix. This would result in faster progression of atherosclerosis, and this has been consistently seen in three previous angiographic studies of patients with coronary artery disease [10, 12, 13] . This strongly suggests that connective tissue remodelling mediated by metalloproteinases contributes to the pathogenesis of atherosclerosis and specifically to the progression of advanced coronary atherosclerosis. The results presented here extend these observations, in that the processes of restenosis that occur after conventional balloon coronary angioplasty can also now be viewed as having an important component of metalloproteinase involvement. This association between angiographic restenosis and 6A6A genotype was not detected in the group of patients who had had a stent implanted. Although this could be due to chance, the sample size of patients with and without a stent is of similar size, and this lack of association suggests that there may be different processes occurring in patients with and without a stent. Both vascular remodelling and neointimal hyperplasia have been implicated in the pathogenesis of restenosis after coronary angioplasty, and the investigation of patients with and without stent implantation allows us in part to differentiate between these two mechanisms. Factors that directly affect neointimal hyperplasia will be more likely to influence restenosis after coronary stenting than after conventional balloon angioplasty alone. Using this approach we reported that the deletion allele of the angiotensin converting enzyme (ACE) gene is a genetic susceptibility risk factor of restenosis in stented patients only, suggesting the involvement of ACE levels in neointimal hyperplasia [14, 15] , and this has been confirmed in some (e.g. [16] ) but not all studies of stented patients (e.g. [17] ). Conversely, factors that affect vascular remodelling will be more easily detected after conventional balloon angioplasty alone. The data presented here confirm and extend the evidence for an effect of low MMP3 levels on vascular remodelling, although without direct measures of MMP3 levels this is an extrapolation based on the in vitro data of the promoter strength differences [11] . It appears from the data that patients with the genotypes 5A5A and 5A6A have the same (smaller) degree of late lumen diameter loss compared to the 6A6A group, although based on a 'co-dominant' model whereby the sequence change affects promoter activity directly, the 5A6A subjects would be expected to have lower MMP3 levels than the 5A5A subjects (with 6A6A subjects the lowest). This suggests that the amount of MMP3 activity present in the 5A6A individuals may be sufficient for adequate remodelling after angioplasty, and that levels are only limiting in the 6A6A subjects, thus resulting in the 'dominant' protective effect from lumen loss associated with the 5A allele. A similar ranking of the genotype effect (i.e. 5A5A=5A6A<6A6A) on changes in vessel wall lumen has been made in some [10, 12] but not all previous studies [13] . A direct test of this hypothesis would require measurement of MMP3 levels in tissue removed at surgery from individuals of different genotype and this has not yet proved technically (or ethically) feasible. Interestingly, it would be predicted that subjects with the genotype 5A5A would have amongst the highest levels of MMP3 and would thus be at risk of plaque rupture and thus myocardial infarction, and this prediction has been borne out by a recent study of patients with unstable angina [18] . Due to the greater dissemination of stent implantation techniques in many countries the majority of patients now undergo elective stent implantations, although to some extent clinical judgment about which patients should receive stents are still made. These observations might thus be useful to help the decision of stent implantation in clinical practice, since patients carrying the 6A6A genotype, who represent roughly 25% of the general population, appear to benefit most from stent implantation compared to those with other genotype. This study was performed on patients that were recruited between 1994 and 1997 at a period where stenting was less common. However the clinical profiles of the patients, their distribution of risk factors and the type of procedures used to perform angioplasty have not changed significantly over this period, and thus the observation of the genotype effect is likely to be still relevant in patients today; indeed no interaction with stent indication could be detected in the stent group. Thus if confirmed by further studies, genotyping may be a useful tool to identify those individuals who will benefit most from this clinical intervention.
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